AR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: To assess the therapeutic effects of AR inhibitors in suppressing the progression of Xp11.2 tRCC, UOK109 and UOK120 cells were treated with MDV3100, a second‐generation antiandrogen.